[go: up one dir, main page]

PE20080094A1 - COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO - Google Patents

COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO

Info

Publication number
PE20080094A1
PE20080094A1 PE2007000509A PE2007000509A PE20080094A1 PE 20080094 A1 PE20080094 A1 PE 20080094A1 PE 2007000509 A PE2007000509 A PE 2007000509A PE 2007000509 A PE2007000509 A PE 2007000509A PE 20080094 A1 PE20080094 A1 PE 20080094A1
Authority
PE
Peru
Prior art keywords
ethyl
methyl
compounds
agonist activity
hydroxyethylamine
Prior art date
Application number
PE2007000509A
Other languages
English (en)
Inventor
Pierre-Jean Colson
Adam D Hughes
Craig Husfeld
Mathai Mammen
Miroslaw Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PE20080094A1 publication Critical patent/PE20080094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

REFERIDA A UN DERIVADO DE DIALQUILFENILO DE FORMULA (I), DONDE R1 ES METILO O ETILO; R2 ES METILO O ETILO. SONCOMPUESTOS PREFERIDOS: ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-DIMETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-DIETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-ETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA UNA COMPOSICION FARMACEUTICA, UN PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR BETA 2 ADRENERGICO Y ANTAGONISTAS DEL RECEPTOR MUSCARINICO Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES PULMONARES
PE2007000509A 2006-04-25 2007-04-24 COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO PE20080094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
PE20080094A1 true PE20080094A1 (es) 2008-02-17

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000509A PE20080094A1 (es) 2006-04-25 2007-04-24 COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO

Country Status (20)

Country Link
US (3) US7524965B2 (es)
EP (1) EP2010489B1 (es)
JP (1) JP2009541209A (es)
KR (1) KR20090005389A (es)
CN (1) CN101426764A (es)
AR (1) AR060647A1 (es)
AU (1) AU2007243481A1 (es)
BR (1) BRPI0710767A2 (es)
CA (1) CA2650530A1 (es)
CO (1) CO6140054A2 (es)
ES (1) ES2391584T3 (es)
IL (1) IL194334A0 (es)
MA (1) MA30556B1 (es)
MX (1) MX2008013555A (es)
NO (1) NO20084603L (es)
PE (1) PE20080094A1 (es)
RU (1) RU2008146383A (es)
TW (1) TW200811105A (es)
WO (1) WO2007127196A2 (es)
ZA (1) ZA200808817B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
UA100400C2 (uk) * 2008-02-06 2012-12-25 Астразенека Аб Похідні спіроциклічних амідів
MX2011011156A (es) 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP3061821B1 (en) 2009-07-22 2019-07-10 Puretech Health LLC Compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
EP3856182B1 (en) 2018-09-28 2025-12-24 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
CN114409556B (zh) * 2022-01-28 2024-10-18 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005087735A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound

Also Published As

Publication number Publication date
NO20084603L (no) 2008-11-19
CO6140054A2 (es) 2010-03-19
MA30556B1 (fr) 2009-07-01
US7687521B2 (en) 2010-03-30
US7524965B2 (en) 2009-04-28
JP2009541209A (ja) 2009-11-26
IL194334A0 (en) 2009-08-03
BRPI0710767A2 (pt) 2011-06-07
US8134006B2 (en) 2012-03-13
MX2008013555A (es) 2008-11-04
EP2010489A2 (en) 2009-01-07
CA2650530A1 (en) 2007-11-08
ZA200808817B (en) 2010-03-31
US20090176833A1 (en) 2009-07-09
US20070249675A1 (en) 2007-10-25
TW200811105A (en) 2008-03-01
WO2007127196A3 (en) 2007-12-21
AR060647A1 (es) 2008-07-02
WO2007127196A2 (en) 2007-11-08
US20100137603A1 (en) 2010-06-03
EP2010489B1 (en) 2012-08-22
KR20090005389A (ko) 2009-01-13
ES2391584T3 (es) 2012-11-28
CN101426764A (zh) 2009-05-06
RU2008146383A (ru) 2010-05-27
AU2007243481A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
PE20080094A1 (es) COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO
NI200700161A (es) Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo
PE20120578A1 (es) Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
BRPI1014877B8 (pt) compostos diamida tendo antagonista do receptor muscarínico e atividade agonista do receptor ß2 adrenérgico, composição farmacêutica e seu uso
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
NO20076481L (no) Benzimidazol-karboksamidforbindelser som 5-HT4 receptorantagonister
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20121433A1 (es) Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
EP4537899A3 (en) Benzimidazole carboxylic acids as glp-1r agonists
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
BRPI0708490B8 (pt) composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto
DK2081572T3 (da) Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
EA201270602A1 (ru) N-((1r,2s,5r)-5-(трет-бутиламино)-2-((s)-3-(7-трет-бутилпиразоло[1,5-а][1,3,5]триазин-4-иламино)-2-оксопирролидин-1-ил)циклогексил)ацетамид в качестве двойного модулятора активности хемокиновых рецепторов, его кристаллические формы и способы получения
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
PE20091330A1 (es) Derivados de 4-aminopirimidina como antagonistas de receptores de histamina h4
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
CR10207A (es) "derivados de acido acético benzo (f) isoindol-2-ilfenil como receptores agonistas de ep4"
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.

Legal Events

Date Code Title Description
FC Refusal